INTRODUCTION: Vascular graft infection is a life threatening situation with significant morbidity and mortality. Bacterial graft infection can lead to false aneurysms, bleeding and sepsis. There are a lot of risky situations where grafts can become infected. It is therefore highly desirable to have a vascular graft that is resistant to infection. In this retrospective clinical study, a silver-impregnated vascular graft was evaluated in various indications. METHODS: Our study included a total of 71 patients who received a silver-impregnated vascular graft during the period from 2013 to 2018. Patients had an aortoiliac localization of vascular graft in 61 cases (86%), and a peripheral localization on the lower limbs in 10 cases (14%). Indications for the use of these special vascular grafts were trophic lesions or gangrene in the lower limbs in 24 cases (34%), suspicious mycotic abdominal aortic aneurysm (mAAA) in 4 cases (5.5%), salmonela aortitis or aneurysms in 4 cases (5.5%), infection of the previous vascular graft in 11 cases (15.5%), other infections in 12 cases (17%), AAA rupture in 10 cases (14%) and other reasons (pre-transplant condition, multiple trauma, graft-enteric fistula) in 6 cases (8.5%). Thirty-day mortality, morbidity, the need for reintervention and amputation, primary and secondary graft patency, and finally the presence of a proven vascular graft infection were evaluated. RESULTS: The 30-day mortality was 19.7%, and morbidity was 42.2%. The primary patency of the vascular graft was 91.5%. Reoperation was necessary in 10 cases (14%) and amputation was necessary in 10 cases (14%). The median length of hospital stay was 13 days and the mean follow-up period was 48 ± 9 months. During the follow-up period, six patients (8.5%) died from reasons unrelated to surgery or without any relation to the vascular graft. Secondary patency after one year was 88%. Infection of the silver graft was observed in three patients (4.2%). CONCLUSIONS: Based on our results, the silver graft is a very suitable alternative for solving infectious, or potentially infectious, situations in vascular surgery. In particular, in urgent or acute cases, a silver graft is often the only option.

Department of Imagine Methods University Hospital in Pilsen Faculty of Medicine in Pilsen Charles University Husova 3 301 00 Plzeň Czech Republic

Vascular Surgery Department University Hospital in Pilsen Faculty of Medicine in Pilsen Charles University Husova 3 301 00 Plzeň Czech Republic

Zobrazit více v PubMed

Batt M., Feugier P., Camou F., Coffy A., Senneville E., Caillon J., Calvet B., Chidiac C., Laurent F., Revest M., et al. A Meta-Analysis of Outcomes after In Situ Reconstructions for Aortic Graft Infection. Angiology. 2018;69:370–379. doi: 10.1177/0003319717710114. PubMed DOI

Gharamti A., Kanafani Z.A. Vascular Graft Infections An update. Infect. Dis. Clin. N. Am. 2018;32:789–809. doi: 10.1016/j.idc.2018.06.003. PubMed DOI

Seeger J.M. Management of patients with prosthetic vascular graft infection. Am. Surg. 2000;66:166–177. PubMed

Blaha L., Bulejčík J., Říha D. Vascular graft infection in the aortoiliac territory—Our view in the light of European Society for Vascular Surgery Guidelines—The retrospective observation study. Perspect. Surg. 2021;100:330–338. doi: 10.33699/pis.2021.100.7.330-338. PubMed DOI

Sebesta P., Stádler P., Sedivý P., Zdráhal P., El Samman K., Jindrák V., Syrůcek M. Radikální operace infekce cévní protézy v aortofemorální pozici s pomocí cerstvého tepenného allograftu: Nase strednedobé zkus-enosti [Radical operation of infected aortofemoral prosthesis using fresh arterial allograft: Our mid-term experience] Rozhl. V Chir. 2011;90:4–13. (In Czech) PubMed

Shiraev T.P., de Boer M., Joseph S., Loa J., Qasabian R. Aortic graft explants—A single institution analysis of incidence and outcomes. Vascular. 2022 doi: 10.1177/17085381211068219. PubMed DOI

Ricco J.-B. InterGard silver bifurcated graft: Features and results of a multicenter clinical study. J. Vasc. Surg. 2006;44:339–346. doi: 10.1016/j.jvs.2006.03.046. PubMed DOI

El-Gamel A. Proximal Aortic Graft Infection: Time for Treatment in an Aortic Centre? Heart Lung Circ. 2022;31:4–6. doi: 10.1016/j.hlc.2021.11.001. PubMed DOI

Puges M., Bérard X., Caradu C., Accoceberry I., Gabriel F., Cazanave C. Fungal Vascular Graft and Endograft Infections are Frequently Associated with Aorto-Enteric Fistulas. Eur. J. Vasc. Endovasc. Surg. 2021;62:819–820. doi: 10.1016/j.ejvs.2021.07.002. PubMed DOI

Rufa M., Ursulescu A., Stan A., Göbel N., Albert M., Franke U.F.W. Cryopreserved aortic homograft, lifeline treatment for infected vascular prosthesis with mediastinal abscess in a re-redo case. J. Surg. Case Rep. 2022;2022:rjab644. doi: 10.1093/jscr/rjab644. PubMed DOI PMC

Kouijzer I.J., Van der Jagt M.F., Bleeker-Rovers C.P., Dirven M., de Mast Q., Poyck P.P. Outcome in Patients after Autologous Femoral Vein Reconstruction for Primary Aortic Infection and Aortic Graft Infection: A Case Series. Ann. Vasc. Surg. 2021;18 doi: 10.1016/j.avsg.2021.11.012. PubMed DOI

Neufang A., Savvidis S. Operative technique and morbidity of superficial femoral vein harvest. Gefässchirurgie. 2016;21:45–54. doi: 10.1007/s00772-016-0170-6. PubMed DOI PMC

Spacek M., Měřička P., Janoušek L., Štádler P., Adamec M., Vlachovský R., Guňka I., Navrátil P., Thieme F., Špunda R., et al. Current vascular allograft procurement, cryopreservation and transplantation techniques in the Czech Republic. Adv. Clin. Exp. Med. 2019;28:529–534. doi: 10.17219/acem/90037. PubMed DOI

Larena-Avellaneda A., Russmann S., Fein M., Debus E.S. Prophylactic use of the silver-acetate–coated graft in arterial occlusive disease: A retrospective, comparative study. J. Vasc. Surg. 2009;50:790–798. doi: 10.1016/j.jvs.2009.05.003. PubMed DOI

Berard X., Puges M., Pinaquy J.-B., Cazanave C., Stecken L., Bordenave L., Pereyre S., M’Zali F. In vitro Evidence of Improved Antimicrobial Efficacy of Silver and Triclosan Containing Vascular Grafts Compared with Rifampicin Soaked Grafts. Eur. J. Vasc. Endovasc. Surg. 2019;57:424–432. doi: 10.1016/j.ejvs.2018.08.053. PubMed DOI

Berger P., Van Herwaarden J.A., Harkisoen S., De Vries J.P., Ekkelenkamp M., Moll F.L. Surgical treatment of infected aortic grafts. J. Cardiovasc. Surg. 2012;53:719–734. PubMed

McGuinness B., Ali K.P., Phillips S., Stacey M. A Scoping Review on the Use of Antibiotic-Impregnated Beads and Applications to Vascular Surgery. Vasc. Endovasc. Surg. 2019;54:147–161. doi: 10.1177/1538574419886957. PubMed DOI

Clemens M.S., Stull M.C., Hata K.W., Heafner T.A., Watson J.D.B., Arthurs Z.M., Propper B.W. Antimicrobial-bonded graft patency in the setting of a polymicrobial infection in swine (Sus scrofa) J. Vasc. Surg. 2017;66:1210–1216. doi: 10.1016/j.jvs.2016.09.040. PubMed DOI

Bisdas T., Beckmann E., Marsch G., Burgwitz K., Wilhelmi M., Kuehn C., Haverich A., Teebken O. Prevention of Vascular Graft Infections with Antibiotic Graft Impregnation Prior to Implantation: In Vitro Comparison between Daptomycin, Rifampin and Nebacetin. Eur. J. Vasc. Endovasc. Surg. 2012;43:448–456. doi: 10.1016/j.ejvs.2011.12.029. PubMed DOI

Mufty H., Eynde J.V.D., Meuris B., Metsemakers W.-J., Van Wijngaerden E., Vandendriessche T., Steenackers H.P., Fourneau I. Pre-clinical in vivo Models of Vascular Graft Coating in the Prevention of Vascular Graft Infection: A Systematic Review. Eur. J. Vasc. Endovasc. Surg. 2021;62:99–118. doi: 10.1016/j.ejvs.2021.02.054. PubMed DOI

Honig S., Seeger P., Rohde H., Kölbel T., Debus E.S., Diener H. Efficacy of antiseptic impregnation of aortic endografts with rifampicin compared to silver against in vitro contamination with four bacteria that frequently cause vascular graft infections. JVS Vasc. Sci. 2020;1:181–189. doi: 10.1016/j.jvssci.2020.06.003. PubMed DOI PMC

Szeberin Z., Münch Z., Fehérvári M., Bíró G., Entz L., Acsády G. Ezüst-acetáttal bevont Dacron grafttal végzett rekonstrukciós érműtétek középtávú eredményei [Mid-term results of silver-coated Dacron graft implanta-tion in aortic and lower extremity revascularization] Magy. Sebészet. 2010;63:369–373. doi: 10.1556/maseb.63.2010.6.3. PubMed DOI

Mufty H., Eynde J.V.D., Steenackers H.P., Metsemakers W.-J., Meuris B., Fourneau I. A systematic review of preclinical data regarding commercial silver-coated vascular grafts. J. Vasc. Surg. 2021;74:1386–1393.e1. doi: 10.1016/j.jvs.2021.04.055. PubMed DOI

Hassen-Khodja R., Sadaghianloo N., Jean-Baptiste É. Matériaux de reconstruction aortique résistants à la contamination bactérienne [Aortic reconstruction with graft materials resistant to bacterial infections] Bull. L’academie Natl. Med. 2013;197:979–991. discussion 991; (In French) PubMed

Kessler V., Klopf J., Eilenberg W., Neumayer C., Brostjan C. AAA Revisited: A Comprehensive Review of Risk Factors, Management, and Hallmarks of Pathogenesis. Biomedicines. 2022;10:94. doi: 10.3390/biomedicines10010094. PubMed DOI PMC

Golemovic M., Skific M., Haluzan D., Pavic P., Cepulic B.G. Ten-year experience with cryopreserved vascular allografts in the Croatian Cardiovascular Tissue Bank. Cell Tissue Bank. 2022:1–18. doi: 10.1007/s10561-022-09992-6. PubMed DOI PMC

Wilson W.R., Bower T.C., Creager M.A., Amin-Hanjani S., O’Gara P.T., Lockhart P.B., Darouiche R.O., Ramlawi B., Derdeyn C., Bolger A.F., et al. Vascular Graft Infections, Mycotic Aneurysms, and Endovascular Infections: A Scientific Statement from the American Heart Association. Circulation. 2016;134:e412–e460. doi: 10.1161/CIR.0000000000000457. PubMed DOI

Bisdas T., Wilhelmi M., Haverich A., Teebken O.E. Cryopreserved arterial homografts vs silver-coated Dacron grafts for abdominal aortic infections with intraoperative evidence of microorganisms. J. Vasc. Surg. 2011;53:1274–1281.e4. doi: 10.1016/j.jvs.2010.11.052. PubMed DOI

Hardman S., Cope A., Swann A., Bell P., Naylor A., Hayes P. An In Vitro Model to Compare the Antimicrobial Activity of Silver-Coated Versus Rifampicin-Soaked Vascular Grafts. Ann. Vasc. Surg. 2004;18:308–313. doi: 10.1007/s10016-004-0042-5. PubMed DOI

Tîlmaciu C.-M., Mathieu M., Lavigne J.-P., Toupet K., Guerrero G., Ponche A., Amalric J., Noël D., Mutin P.H. In vitro and in vivo characterization of antibacterial activity and biocompatibility: A study on silver-containing phosphonate monolayers on titanium. Acta Biomater. 2015;15:266–277. doi: 10.1016/j.actbio.2014.12.020. PubMed DOI

Mohseni M., Shamloo A., Aghababaei Z., Vossoughi M., Moravvej H. Antimicrobial Wound Dressing Containing Silver Sulfadiazine with High Biocompatibility: In Vitro Study. Artif. Organs. 2016;40:765–773. doi: 10.1111/aor.12682. PubMed DOI

Rozhin A., Batasheva S., Kruychkova M., Cherednichenko Y., Rozhina E., Fakhrullin R. Biogenic Silver Nanoparticles: Synthesis and Application as Antibacterial and Antifungal Agents. Micromachines. 2021;12:1480. doi: 10.3390/mi12121480. PubMed DOI PMC

Al-Zoubi N.A., Al-Shawwa Z. Complications of endo-vascular aortic repair for abdominal aortic aneurysm: A retrospective single-centre experience. Ann. Med. Surg. 2021;64:102219. doi: 10.1016/j.amsu.2021.102219. PubMed DOI PMC

Berard X., Stecken L., Pinaquy J.-B., Cazanave C., Puges M., Pereyre S., Bordenave L., M’Zali F. Comparison of the Antimicrobial Properties of Silver Impregnated Vascular Grafts with and without Triclosan. Eur. J. Vasc. Endovasc. Surg. 2016;51:285–292. doi: 10.1016/j.ejvs.2015.10.016. PubMed DOI